These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 19808128)
61. Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging. Chen F; Suzuki Y; Nagai N; Sun X; Wang H; Yu J; Marchal G; Ni Y Radiology; 2007 Aug; 244(2):429-38. PubMed ID: 17581889 [TBL] [Abstract][Full Text] [Related]
62. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Riff DS; Duckor S; Gottlieb I; Diamond E; Soulier S; Raymond G; Boesing SE Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878 [TBL] [Abstract][Full Text] [Related]
63. A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Gan TJ; Daniels SE; Singla N; Hamilton DA; Carr DB Anesth Analg; 2012 Nov; 115(5):1212-20. PubMed ID: 22886837 [TBL] [Abstract][Full Text] [Related]
64. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386 [TBL] [Abstract][Full Text] [Related]
65. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373 [TBL] [Abstract][Full Text] [Related]
66. Antipyretic efficacy and tolerability of a single intravenous dose of the acetaminophen prodrug propacetamol in children: a randomized, double-blind, placebo-controlled trial. Walson PD; Jones J; Chesney R; Rodarte A Clin Ther; 2006 May; 28(5):762-9. PubMed ID: 16861098 [TBL] [Abstract][Full Text] [Related]
67. A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects. Becker NP; Haberland A; Wenzel K; Göttel P; Wallukat G; Davideit H; Schulze-Rothe S; Hönicke AS; Schimke I; Bartel S; Grossmann M; Sinn A; Iavarone L; Boergermann JH; Prilliman K; Golor G; Müller J; Becker S Clin Drug Investig; 2020 May; 40(5):433-447. PubMed ID: 32222912 [TBL] [Abstract][Full Text] [Related]
69. Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Nagai N; De Mol M; Van Hoef B; Verstreken M; Collen D Blood; 2001 May; 97(10):3086-92. PubMed ID: 11342434 [TBL] [Abstract][Full Text] [Related]
70. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Dyker AG; Edwards KR; Fayad PB; Hormes JT; Lees KR Stroke; 1999 Oct; 30(10):2038-42. PubMed ID: 10512904 [TBL] [Abstract][Full Text] [Related]
71. Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers. Eldon MA; Smith RA; Leese PT; Daigle AE; Katz DV; Richieri SP J Clin Pharmacol; 1990 Apr; 30(4):352-7. PubMed ID: 2140370 [TBL] [Abstract][Full Text] [Related]
73. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Grotta J; Clark W; Coull B; Pettigrew LC; Mackay B; Goldstein LB; Meissner I; Murphy D; LaRue L Stroke; 1995 Apr; 26(4):602-5. PubMed ID: 7709405 [TBL] [Abstract][Full Text] [Related]
74. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Schenk DB; Koller M; Ness DK; Griffith SG; Grundman M; Zago W; Soto J; Atiee G; Ostrowitzki S; Kinney GG Mov Disord; 2017 Feb; 32(2):211-218. PubMed ID: 27886407 [TBL] [Abstract][Full Text] [Related]
75. A Clinical Trial on Biological Half Life of Bioactive Protein from Lumbricus rubellus, DLBS1033 in Healthy Volunteers. Gayatri A; Nafrialdi N; Setiabudy RD; Tjandrawinata RR; Rachman A; Louisa M Acta Med Indones; 2018 Jul; 50(3):208-214. PubMed ID: 30333270 [TBL] [Abstract][Full Text] [Related]
76. Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. Dias C; Abosaleem B; Crispino C; Gao B; Shaywitz A AAPS PharmSciTech; 2015 Oct; 16(5):1101-7. PubMed ID: 25693652 [TBL] [Abstract][Full Text] [Related]
77. Recombinant human microplasmin: production and potential therapeutic properties. Nagai N; Demarsin E; Van Hoef B; Wouters S; Cingolani D; Laroche Y; Collen D J Thromb Haemost; 2003 Feb; 1(2):307-13. PubMed ID: 12871505 [TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics of high-dose intravenous melatonin in humans. Andersen LP; Werner MU; Rosenkilde MM; Fenger AQ; Petersen MC; Rosenberg J; Gögenur I J Clin Pharmacol; 2016 Mar; 56(3):324-9. PubMed ID: 26184078 [TBL] [Abstract][Full Text] [Related]
79. Safety and tolerability of 619C89 after acute stroke. Muir KW; Hamilton SJ; Lunnon MW; Hobbiger S; Lees KR Cerebrovasc Dis; 1998; 8(1):31-7. PubMed ID: 9645979 [TBL] [Abstract][Full Text] [Related]
80. A First-in-Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers. Hazan Z; Adamsky K; Lucassen A; Levin LA Clin Pharmacol Drug Dev; 2020 Apr; 9(3):366-374. PubMed ID: 31250992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]